MedTrace Logo

Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition

NCT05721326 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1330

Last updated 2026-01-13

No results posted yet for this study

Summary

The goal of this sequential study design is to increase genetic testing in those meeting national clinical guidelines. The main question it aims to answer is: which intervention is most effective in uptake of genetic testing for the target population? Participants will receive genetic testing and counseling that may initiate life-saving screenings.

Conditions

  • Genetic Predisposition to Disease
  • Breast Cancer Female
  • Ovarian Cancer
  • Hereditary Breast and Ovarian Cancer
  • Hereditary Cancer Syndrome
  • Hereditary Diseases
  • Gene Mutation-Related Cancer

Interventions

OTHER

Sequential EHR Communications

The intervention includes 3 message types: an EHR message, followed by a text message, followed by physician nudge. Each subsequent type will be activated if the previous type does not yield a response.

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
25 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05721326 on ClinicalTrials.gov